Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1996;93:1155-1159

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davidson, N. C.
Right arrow Articles by Struthers, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davidson, N. C.
Right arrow Articles by Struthers, A. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

(Circulation. 1996;93:1155-1159.)
© 1996 American Heart Association, Inc.


Articles

C-Type Natriuretic Peptide

An Endogenous Inhibitor of Vascular Angiotensin-Converting Enzyme Activity

Neil C. Davidson, MB, MRCP; Craig S. Barr, MB, MRCP; Allan D. Struthers, MD, FRCP

From the Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, UK.

Correspondence to Prof A.D. Struthers, Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, DD1 9SY UK.

Background Atrial and B-type natriuretic peptide are both known to be antagonists of the renin-angiotensin system. C-type natriuretic peptide (CNP) is a new member of this family except that its principal source is the vascular endothelium. This study tested the hypothesis that CNP is a local inhibitor of vascular angiotensin-converting enzyme (ACE) activity.

Methods and Results Vascular ACE activity was assessed by the differential vascular response to angiotensin I and angiotensin II. Healthy male volunteers were studied with the use of brachial artery infusions of angiotensin I and angiotensin II at two doses, with and without coinfusion of CNP at 500 pmol/min (n=8) and hydralazine at 10 µg/min (n=8) (as a nonspecific vasodilator control). CNP alone and hydralazine alone caused similar increases in forearm blood flow (CNP+, 93.0±14.8%; hydralazine+, 84.2±22.6%). CNP inhibited the vasoconstrictive effect of angiotensin I (reduction in overall effect with CNP, 56.8±12.9%; P<.001) but not that of angiotensin II. Hydralazine did not significantly inhibit the effect of either angiotensin I or angiotensin II.

Conclusions This evidence of a differential effect of CNP on the vascular response to angiotensin I but not to angiotensin II suggests that CNP acts as a local endogenous regulator of vascular ACE activity in the human forearm resistance vessels.


Key Words: peptides • angiotensin • natriuretic peptides • atrial natriuretic factor • vasoconstriction




This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
C. J. Kelsall, A. H. Chester, M. Amrani, and D. R.J. Singer
C-Type Natriuretic Peptide Relaxes Human Coronary Artery Bypass Grafts Preconstricted by Endothelin-1
Ann. Thorac. Surg., October 1, 2005; 80(4): 1347 - 1351.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
M. Komarek, A. Bernheim, R. Schindler, R. Steden, W. Kiowski, and H. P. B.-L. Rocca
Vascular Effects of Natriuretic Peptides in Healthy Men
Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2004; 9(4): 263 - 270.
[Abstract] [PDF]


Home page
HypertensionHome page
S. P. Wright, T. C.R. Prickett, R. N. Doughty, C. Frampton, G. D. Gamble, T. G. Yandle, N. Sharpe, and M. Richards
Amino-Terminal Pro-C-Type Natriuretic Peptide in Heart Failure
Hypertension, January 1, 2004; 43(1): 94 - 100.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. R. Kalra, J. R. Clague, A. P. Bolger, S. D. Anker, P. A. Poole-Wilson, A. D. Struthers, and A. J. Coats
Myocardial Production of C-Type Natriuretic Peptide in Chronic Heart Failure
Circulation, February 4, 2003; 107(4): 571 - 573.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
C A J Farquharson and A D Struthers
Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure
Heart, December 1, 2002; 88(5): 475 - 480.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. M. McEniery, I. B. Wilkinson, D. G. Jenkins, and D. J. Webb
Endogenous Endothelin-1 Limits Exercise-Induced Vasodilation in Hypertensive Humans
Hypertension, August 1, 2002; 40(2): 202 - 206.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. A. J. Farquharson and A. D. Struthers
Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure
J. Am. Coll. Cardiol., March 6, 2002; 39(5): 767 - 775.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
P. R Kalra, S. D Anker, and A. J.S Coats
Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin
Cardiovasc Res, August 15, 2001; 51(3): 495 - 509.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Walther, H.-P. Schuitheiss, and C. Tschope
Impaired angiotensin II regulation of renal C-type natriuretic peptide mRNA expression in experimental diabetes mellitus
Cardiovasc Res, August 15, 2001; 51(3): 562 - 566.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P.R Kalra, S.D Anker, A.D Struthers, and A.J.S Coats
The role of C-type natriuretic peptide in cardiovascular medicine
Eur. Heart J., June 2, 2001; 22(12): 997 - 1007.
[PDF]


Home page
J Am Coll CardiolHome page
N. C. Davidson and A. D. Struthers
C-type natriuretic peptide and vascular remodeling
J. Am. Coll. Cardiol., January 1, 2001; 37(1): 333 - 333.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. Shimokawa, K. Morishige, and A. Takeshita
C-type natriuretic peptide and vascular remodeling: Reply
J. Am. Coll. Cardiol., January 1, 2001; 37(1): 333 - 334.
[Full Text] [PDF]


Home page
CirculationHome page
C. A. J. Farquharson and A. D. Struthers
Spironolactone Increases Nitric Oxide Bioactivity, Improves Endothelial Vasodilator Dysfunction, and Suppresses Vascular Angiotensin I/Angiotensin II Conversion in Patients With Chronic Heart Failure
Circulation, February 15, 2000; 101(6): 594 - 597.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
D. Rehemudula, T. Nakayama, M. Soma, Y. Takahashi, J. Uwabo, M. Sato, Y. Izumi, K. Kanmatsuse, and Y. Ozawa
Structure of the Type B Human Natriuretic Peptide Receptor Gene and Association of a Novel Microsatellite Polymorphism With Essential Hypertension
Circ. Res., March 19, 1999; 84(5): 605 - 610.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
N. C. Davidson and A. D. Struthers
Nitric Oxide Regulates Renin Release During Salt Depletion but Does Not Alter Angiotensin Responses in Normal Humans
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(1): 9 - 14.
[Abstract] [PDF]


Home page
HypertensionHome page
M. Nagase, K. Ando, T. Katafuchi, A. Kato, S. Hirose, and T. Fujita
Role of Natriuretic Peptide Receptor Type C in Dahl Salt-Sensitive Hypertensive Rats
Hypertension, August 1, 1997; 30(2): 177 - 183.
[Abstract] [Full Text]


Home page
HypertensionHome page
T.-H. Chun, H. Itoh, Y. Ogawa, N. Tamura, K. Takaya, T. Igaki, J. Yamashita, K. Doi, M. Inoue, K. Masatsugu, et al.
Shear Stress Augments Expression of C-Type Natriuretic Peptide and Adrenomedullin
Hypertension, June 1, 1997; 29(6): 1296 - 1302.
[Abstract] [Full Text]